Omnicell (NASDAQ:OMCL) Updates Q3 2026 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.350-0.430 for the period, compared to the consensus estimate of 0.430. The company issued revenue guidance of $301.0 million-$307.0 million, compared to the consensus revenue estimate of $312.6 million. Omnicell also updated its FY 2026 guidance to 2.150-2.300 EPS.

Analysts Set New Price Targets

OMCL has been the topic of several recent analyst reports. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Zacks Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wells Fargo & Company boosted their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, April 23rd. Finally, KeyCorp upped their price target on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $59.86.

Omnicell Price Performance

Shares of Omnicell stock opened at $41.40 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The firm has a fifty day simple moving average of $42.29 and a 200-day simple moving average of $41.23. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 94.09, a PEG ratio of 1.11 and a beta of 0.96. Omnicell has a 1-year low of $28.90 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, sell-side analysts expect that Omnicell will post 1.31 earnings per share for the current year.

Insider Transactions at Omnicell

In related news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This represents a 4.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.92% of the company’s stock.

Hedge Funds Weigh In On Omnicell

Several institutional investors have recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. acquired a new position in Omnicell in the second quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Omnicell during the fourth quarter worth approximately $58,000. Parkside Financial Bank & Trust raised its stake in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the last quarter. Van ECK Associates Corp raised its stake in shares of Omnicell by 75.1% in the fourth quarter. Van ECK Associates Corp now owns 2,294 shares of the company’s stock valued at $104,000 after acquiring an additional 984 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Omnicell by 385.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after acquiring an additional 3,932 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.